185 related articles for article (PubMed ID: 38023710)
1. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Zhu S; Fan S; Tang T; Huang J; Zhou H; Huang C; Chen Y; Qian F
Bioeng Transl Med; 2023 Nov; 8(6):e10523. PubMed ID: 38023710
[TBL] [Abstract][Full Text] [Related]
2. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
3. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
Dalvin LA; Starr MR; AbouChehade JE; Damento GM; Garcia M; Shah SM; Hodge DO; Meissner I; Bakri SJ; Iezzi R
JAMA Ophthalmol; 2019 May; 137(5):483-490. PubMed ID: 30703203
[TBL] [Abstract][Full Text] [Related]
4. A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration.
Huang C; Wang Y; Huang J; Liu H; Chen Z; Jiang Y; Chen Y; Qian F
Bioeng Transl Med; 2024 Mar; 9(2):e10632. PubMed ID: 38435828
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Rezende FA; Lapalme E; Qian CX; Smith LE; SanGiovanni JP; Sapieha P
Am J Ophthalmol; 2014 Nov; 158(5):1071-78. PubMed ID: 25089351
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
7. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
[TBL] [Abstract][Full Text] [Related]
9. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept in wet AMD: specific role and optimal use.
Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
12. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal anti-VEGF therapy is not associated with a higher risk of all-cause mortality in patients with macular oedema caused by posterior segment vascular diseases.
Loukovaara S; Haukka J
Acta Ophthalmol; 2021 Sep; 99(6):e893-e898. PubMed ID: 33389820
[TBL] [Abstract][Full Text] [Related]
14. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Shah SM; Boopathiraj N; Starr MR; Dalvin LA; AbouChehade J; Damento G; Garcia MD; Hodge DO; Bakri SJ; Sit AJ; Iezzi R
Am J Ophthalmol; 2022 Nov; 243():98-108. PubMed ID: 35932820
[TBL] [Abstract][Full Text] [Related]
15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
16. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
[TBL] [Abstract][Full Text] [Related]
17. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
18. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting.
Matsubara H; Matsui Y; Miyata R; Ichio A; Chujo S; Enomoto H; Sugimoto M; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1867-1876. PubMed ID: 35094126
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
Prahs P; Brandl C; Helbig H; Volz C
Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
[No Abstract] [Full Text] [Related]
20. Disease progression pathways of wet AMD: opportunities for new target discovery.
Wolf AT; Harris A; Oddone F; Siesky B; Verticchio Vercellin A; Ciulla TA
Expert Opin Ther Targets; 2022 Jan; 26(1):5-12. PubMed ID: 35060431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
